Skip to main content

Advertisement

SpringerLink
Log in

An overview of chondrosarcoma with a focus on nanoscale therapeutics

  • Review
  • Published:
Journal of Pharmaceutical Investigation Aims and scope Submit manuscript

Abstract

Background

Chondrosarcoma (CHS) is the second most common sarcoma. However, pathogenesis and etiology of this malignant tumor are still unclear. The primary treatment method for CHS is surgery, and CHS is often resistant to conventional chemotherapy. There are various types of nanoscale therapeutics, such as liposomes, micelles, polymeric nanoparticles, and protein-based nanotherapeutics, which have shown promising results in the treatment of CHSs that are not capable of being surgically removed.

Area covered

The genetics and molecular targets of CHS and its diagnostic features observed by various modalities are introduced. Diverse types of nanoscale therapeutics and their clinical benefits in the treatment of cancer are also described. In addition, the current application of nanotechnologies to CHS treatment is discussed with various nanoplatforms designed for CHS.

Expert opinion

Nanotechnology-based approaches have been investigated to overcome the chemo-resistance of CHS. In particular, for CHS patients with no surgical treatment options, nanomedicine is one of the promising strategies for cancer treatment, along with the immunotherapy that is being spotlighted nowadays. We speculate that the combination of nano- and immuno-therapeutics would be a breakthrough in unresectable CHS treatment, as can be seen in the case of nivolumab plus nanoparticle albumin-bound rapamycin that has shown excellent clinical outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Ahmed AR, Tan T-S, Unni KK, Collins MS, Wenger DE, Sim FH (2003) Secondary chondrosarcoma in osteochondroma: report of 107 patients. Clin Orthop Relat Res 411:193–206

    Article  Google Scholar 

  • Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, Pollock R, O’Donnell P, Grigoriadis A, Diss T (2011) IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 224:334–343

    Article  CAS  PubMed  Google Scholar 

  • Aoki J, Sone S, Fujioka F, Terayama K, Ishii K, Karakida O, Imai S, Sakai F, Imai Y (1991) MR of enchondroma and chondrosarcoma: rings and arcs of Gd-DTPA enhancement. J Comput Assist Tomogr 15:1011–1016

    Article  CAS  PubMed  Google Scholar 

  • Ashtikar M, Nagarsekar K, Fahr A (2016) Transdermal delivery from liposomal formulations—evolution of the technology over the last three decades. J Control Release 242:126–140

    Article  CAS  PubMed  Google Scholar 

  • Aviel-Ronen S, Zadok O, Vituri A, Nass D, Schwartz I, Avivi C, Barshack I (2016) α-Methylacyl-CoA racemase (AMACR) expression in chordomas differentiates them from chondrosarcomas. Sci Rep 6:1–8

    Article  CAS  Google Scholar 

  • Bagley L, Kneeland J, Dalinka MK, Bullough P, Brooks J (1993) Unusual behavior of clear cell chondrosarcoma. Skelet Radiol 22:279–282

    Article  CAS  Google Scholar 

  • Banik BL, Fattahi P, Brown JL (2016) Polymeric nanoparticles: the future of nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol 8:271–299

    Article  PubMed  Google Scholar 

  • Barenholz YC (2012) Doxil®—the first FDA-approved nano-drug: lessons learned. J Control Release 160:117–134

    Article  CAS  PubMed  Google Scholar 

  • Bell DM, Leung KK, Wheatley SC, Ng LJ, Zhou S, Ling KW, Sham MH, Koopman P, Tam PP, Cheah KS (1997) SOX9 directly regulates the type-ll collagen gene. Nat Genet 16:174–178

    Article  CAS  PubMed  Google Scholar 

  • Benoist-Lasselin C, De Margerie E, Gibbs L, Cormier S, Silve C, Nicolas G, Lemerrer M, Mallet J-F, Munnich A, Bonaventure J (2006) Defective chondrocyte proliferation and differentiation in osteochondromas of MHE patients. Bone 39:17–26

    Article  CAS  PubMed  Google Scholar 

  • Bernard SA, Murphey MD, Flemming DJ, Kransdorf MJ (2010) Improved differentiation of benign osteochondromas from secondary chondrosarcomas with standardized measurement of cartilage cap at CT and MR imaging. Radiology 255:857–865

    Article  PubMed  Google Scholar 

  • Bhattacharyya N, Pechhold K, Shahjee H, Zappala G, Elbi C, Raaka B, Wiench M, Hong J, Rechler MM (2006) Nonsecreted insulin-like growth factor binding protein-3 (IGFBP-3) can induce apoptosis in human prostate cancer cells by IGF-independent mechanisms without being concentrated in the nucleus. J Biol Chem 281:24588–24601

    Article  CAS  PubMed  Google Scholar 

  • Blackwell J (1993) Mesenchymal chondrosarcoma arising in fibrous dysplasia of the femur. J Clin Pathol 46:961–962

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bloem J, Reiser M, Vanel D (1990) Magnetic resonance contrast agents in the evaluation of the musculoskeletal system. Magn Reson Q 6:136–163

    CAS  PubMed  Google Scholar 

  • Bloem JL, Mulder JD (1985) Chondroblastoma: a clinical and radiological study of 104 cases. Skelet Radiol 14:1–9

    Article  CAS  Google Scholar 

  • Boeuf S, Bovée JV, Lehner B, Van Den Akker B, Van Ruler M, Cleton-Jansen A-M, Richter W (2012) BMP and TGFbeta pathways in human central chondrosarcoma: enhanced endoglin and Smad 1 signaling in high grade tumors. BMC Cancer 12:488

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Borsig L, Wolf MJ, Roblek M, Lorentzen A, Heikenwalder M (2014) Inflammatory chemokines and metastasis—tracing the accessory. Oncogene 33:3217–3224

    Article  CAS  PubMed  Google Scholar 

  • Bovée JV, Van Den Broek LJ, Cleton-Jansen A-M, Hogendoorn PC (2000) Up-regulation of PTHrP and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma. Lab Investig 80:1925–1933

    Article  PubMed  Google Scholar 

  • Bovée JV (2002) Bone: chondrosarcoma. Atlas Genet Cytogenet Oncol Haematol 6:235–238

    Google Scholar 

  • Bovée JV, Hogendoorn PC, Wunder JS, Alman BA (2010) Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. Nat Rev Cancer 10:481–488

    Article  PubMed  CAS  Google Scholar 

  • Bresnick AR, Weber DJ, Zimmer DB (2015) S100 proteins in cancer. Nat Rev Cancer 15:96–109

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Briscoe J, Thérond PP (2013) The mechanisms of Hedgehog signalling and its roles in development and disease. Nat Rev Mol Cell Biol 14:416–429

    Article  PubMed  CAS  Google Scholar 

  • Brown RE, Boyle JL (2003) Mesenchymal chondrosarcoma: molecular characterization by a proteomic approach, with morphogenic and therapeutic implications. Ann Clin Lab Sci 33:131–141

    CAS  PubMed  Google Scholar 

  • Bruce JL, Hurford RK Jr, Classon M, Koh J, Dyson N (2000) Requirements for cell cycle arrest by p16INK4a. Mol Cell 6:737–742

    Article  CAS  PubMed  Google Scholar 

  • Camidge DR, Herbst RS, Gordon MS, Eckhardt SG, Kurzrock R, Durbin B, Ing J, Tohnya TM, Sager J, Ashkenazi A (2010) A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res 16:1256–1263

    Article  CAS  PubMed  Google Scholar 

  • Campbell VT, Nadesan P, Ali SA, Wang CYY, Whetstone H, Poon R, Wei Q, Keilty J, Proctor J, Wang LW (2014) Hedgehog pathway inhibition in chondrosarcoma using the smoothened inhibitor IPI-926 directly inhibits sarcoma cell growth. Mol Cancer Ther 13:1259–1269

    Article  CAS  PubMed  Google Scholar 

  • Chakkalakal SA, Uchibe K, Convente MR, Zhang D, Economides AN, Kaplan FS, Pacifici M, Iwamoto M, Shore EM (2016) Palovarotene inhibits heterotopic ossification and maintains limb mobility and growth in mice with the human ACVR1R206H Fibrodysplasia Ossificans Progressiva (FOP) mutation. J Bone Miner Res 31:1666–1675

    Article  CAS  PubMed  Google Scholar 

  • Chidambaram M, Manavalan R, Kathiresan K (2011) Nanotherapeutics to overcome conventional cancer chemotherapy limitations. J Pharm Pharm Sci 14:67–77

    Article  PubMed  Google Scholar 

  • Chow WA (2018) Chondrosarcoma: biology, genetics, and epigenetics. F1000Res 7:1826

    Article  CAS  Google Scholar 

  • Corradi D, Bacchini P, Campanini N, Bertoni F (2006) Aggressive clear cell chondrosarcomas: do distinctive characteristics exist? A report of 4 cases. Arch Pathol Lab Med 130:1673–1679

    Article  PubMed  Google Scholar 

  • Curran T, Ng JM (2008) Hedgehog’s other great trick. Nature 455:293–294

    Article  CAS  PubMed  Google Scholar 

  • Dahlin DC, Beabout JW (1971) Dedifferentiation of low-grade chondrosarcomas. Cancer 28:461–466

    Article  CAS  PubMed  Google Scholar 

  • Damron TA, Ward WG, Stewart A (2007) Osteosarcoma, chondrosarcoma, and Ewing’s sarcoma: national cancer data base report. Clin Orthop Relat Res 459:40–47

    Article  PubMed  Google Scholar 

  • De Beuckeleer LH, De Schepper A, Ramon F (1996) Magnetic resonance imaging of cartilaginous tumors: is it useful or necessary? Skelet Radiol 25:137–141

    Article  Google Scholar 

  • De Jong Y, Van Oosterwijk J, Kruisselbrink A, Briaire-De Bruijn I, Agrogiannis G, Baranski Z, Cleven A, Cleton-Jansen A, Van De Water B, Danen E (2016) Targeting survivin as a potential new treatment for chondrosarcoma of bone. Oncogenesis 5:e222

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • De Jong Y, Monderer D, Brandinelli E, Monchanin M, Van Den Akker BE, Van Oosterwijk JG, Blay JY, Dutour A, Bovée JV (2018) Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma. Oncogenesis 7:1–9

    Article  CAS  Google Scholar 

  • Dieterich LC, Seidel CD, Detmar M (2014) Lymphatic vessels: new targets for the treatment of inflammatory diseases. Angiogenesis 17:359–371

    Article  CAS  PubMed  Google Scholar 

  • Donati D, Yin J-Q, Colangeli M, Colangeli S, Di Bella C, Bacchini P, Bertoni F (2008) Clear cell chondrosarcoma of bone: long time follow-up of 18 cases. Arch Orthop Trauma Surg 128:137–142

    Article  PubMed  Google Scholar 

  • Duchman KR, Lynch CF, Buckwalter JA, Miller BJ (2014) Estimated cause-specific survival continues to improve over time in patients with chondrosarcoma. Clin Orthop Relat Res 472:2516–2525

    Article  PubMed  PubMed Central  Google Scholar 

  • Ediriwickrema A, Saltzman WM (2015) Nanotherapy for cancer: targeting and multifunctionality in the future of cancer therapies. ACS Biomater Sci Eng 1:64–78

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Evans HL, Ayala AG, Romsdahl MM (1977) Prognostic factors in chondrosarcoma of bone. A clinicopathologic analysis with emphasis on histologic grading. Cancer 40:818–831

    Article  CAS  PubMed  Google Scholar 

  • Evola FR, Costarella L, Pavone V, Caff G, Cannavò L, Sessa A, Avondo S, Sessa G (2017) Biomarkers of osteosarcoma, chondrosarcoma, and Ewing sarcoma. Front Pharmacol 8:150

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Fan T, Yu X, Shen B, Sun L (2017) Peptide self-assembled nanostructures for drug delivery applications. J Nanomater 2017:4562474

    Google Scholar 

  • Feng X-H, Derynck R (2005) Specificity and versatility in TGF-β signaling through Smads. Annu Rev Cell Dev Biol 21:659–693

    Article  CAS  PubMed  Google Scholar 

  • Ferrer-Santacreu EM, Ortiz-Cruz EJ, González-López JM, Pérez Fernández E (2012) Enchondroma versus low-grade chondrosarcoma in appendicular skeleton: clinical and radiological criteria. J Oncol 2012:437958

    Article  PubMed  PubMed Central  Google Scholar 

  • Fletcher CD, Unni KK, Mertens F (2002) Pathology and genetics of tumours of soft tissue and bone. IARC Press, Lyon

    Google Scholar 

  • Füredi A, Szebényi K, Tóth S, Cserepes M, Hámori L, Nagy V, Karai E, Vajdovich P, Imre T, Szabó P (2017) PEGylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer. J Control Release 261:287–296

    Article  PubMed  CAS  Google Scholar 

  • Golombek SK, May J-N, Theek B, Appold L, Drude N, Kiessling F, Lammers T (2018) Tumor targeting via EPR: Strategies to enhance patient responses. Adv Drug Deliv Rev 130:17–38

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gordon EM, Chua-Alcala VS, Kim K, Baby R, Angel N, Quon D, Wong S, Chawla SP (2019) A phase I/II investigation of nivolumab and ABI-009 (nab-sirolimus) in advanced undifferentiated pleomorphic sarcoma (UPS), liposarcoma (LPS), chondrosarcoma (CS), osteosarcoma (OS), and Ewing sarcoma: preliminary efficacy and safety results. J Clin Oncol 37:11057

    Article  Google Scholar 

  • Green M, Manikhas G, Orlov S, Afanasyev B, Makhson A, Bhar P, Hawkins M (2006) Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 17:1263–1268

    Article  CAS  PubMed  Google Scholar 

  • Grimer RJ, Gosheger G, Taminiau A, Biau D, Matejovsky Z, Kollender Y, San-Julian M, Gherlinzoni F, Ferrari C (2007) Dedifferentiated chondrosarcoma: prognostic factors and outcome from a European group. Eur J Cancer 43:2060–2065

    Article  PubMed  Google Scholar 

  • Grote H, Schneider-Stock R, Neumann W, Roessner A (2000) Mutation of p53 with loss of heterozygosity in the osteosarcomatous component of a dedifferentiated chondrosarcoma. Virchows Arch 436:494–497

    Article  CAS  PubMed  Google Scholar 

  • Hafner A, Bulyk ML, Jambhekar A, Lahav G (2019) The multiple mechanisms that regulate p53 activity and cell fate. Nat Rev Mol Cell Biol 20:199–210

    Article  CAS  PubMed  Google Scholar 

  • Hallor KH, Staaf J, Bovée JV, Hogendoorn PC, Cleton-Jansen A-M, Knuutila S, Savola S, Niini T, Brosjö O, Bauer HC (2009) Genomic profiling of chondrosarcoma: chromosomal patterns in central and peripheral tumors. Clin Cancer Res 15:2685–2694

    Article  CAS  PubMed  Google Scholar 

  • Hameetman L, Kok P, Eilers PH, Cleton-Jansen A-M, Hogendoorn PC, Bovée JV (2005) The use of Bcl-2 and PTHLH immunohistochemistry in the diagnosis of peripheral chondrosarcoma in a clinicopathological setting. Virchows Arch 446:430–437

    Article  PubMed  Google Scholar 

  • Hameetman L, Rozeman LB, Lombaerts M, Oosting J, Taminiau AH, Cleton-Jansen AM, Bovée JV, Hogendoorn PC (2006) Peripheral chondrosarcoma progression is accompanied by decreased Indian Hedgehog signalling. J Pathol 209:501–511

    Article  CAS  PubMed  Google Scholar 

  • Ho L, Stojanovski A, Whetstone H, Wei QX, Mau E, Wunder JS, Alman B (2009) Gli2 and p53 cooperate to regulate IGFBP-3-mediated chondrocyte apoptosis in the progression from benign to malignant cartilage tumors. Cancer Cell 16:126–136

    Article  CAS  PubMed  Google Scholar 

  • Homsi J, Cubitt C, Daud A (2007) The Src signaling pathway: a potential target in melanoma and other malignancies. Expert Opin Ther Targets 11:91–100

    Article  CAS  PubMed  Google Scholar 

  • Horton WE Jr, Feng L, Adams C (1998) Chondrocyte apoptosis in development, aging and disease. Matrix Biol 17:107–115

    Article  CAS  PubMed  Google Scholar 

  • Huang C-Y, Chang A-C, Chen H-T, Wang S-W, Lo Y-S, Tang C-H (2016) Adiponectin promotes VEGF-C-dependent lymphangiogenesis by inhibiting miR-27b through a CaMKII/AMPK/p38 signaling pathway in human chondrosarcoma cells. Clin Sci 130:1523–1533

    Article  CAS  Google Scholar 

  • Huvos AG (1987) Bone tumors: diagnosis, treatment and prognosis. Saunders, Philadelphia

    Google Scholar 

  • Italiano A, Mir O, Cioffi A, Palmerini E, Piperno-Neumann S, Perrin C, Chaigneau L, Penel N, Duffaud F, Kurtz J (2013) Advanced chondrosarcomas: role of chemotherapy and survival. Ann Oncol 24:2916–2922

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jennes I, Pedrini E, Zuntini M, Mordenti M, Balkassmi S, Asteggiano CG, Casey B, Bakker B, Sangiorgi L, Wuyts W (2009) Multiple osteochondromas: mutation update and description of the multiple osteochondromas mutation database (MOdb). Hum Mutat 30:1620–1627

    Article  CAS  PubMed  Google Scholar 

  • Jeong W, Kim H-J (2018) Biomarkers of chondrosarcoma. J Clin Pathol 71:579–583

    Article  CAS  PubMed  Google Scholar 

  • Jhaveri AM, Torchilin VP (2014) Multifunctional polymeric micelles for delivery of drugs and siRNA. Front Pharmacol 5:77

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Jiang X, Dutton CM, Qi WN, Block JA, Garamszegi N, Scully SP (2005) siRNA mediated inhibition of MMP-1 reduces invasive potential of a human chondrosarcoma cell line. J Cell Physiol 202:723–730

    Article  CAS  PubMed  Google Scholar 

  • Kaim AH, Hügli R, Bonél HM, Jundt G (2002) Chondroblastoma and clear cell chondrosarcoma: radiological and MRI characteristics with histopathological correlation. Skelet Radiol 31:88–95

    Article  Google Scholar 

  • Kale J, Osterlund EJ, Andrews DW (2018) BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ 25:65–80

    Article  CAS  PubMed  Google Scholar 

  • Kamachi Y, Kondoh H (2013) Sox proteins: regulators of cell fate specification and differentiation. Development 140:4129–4144

    Article  CAS  PubMed  Google Scholar 

  • Kedar U, Phutane P, Shidhaye S, Kadam V (2010) Advances in polymeric micelles for drug delivery and tumor targeting. Nanomedicine 6:714–729

    Article  CAS  PubMed  Google Scholar 

  • Khongorzul P, Ling CJ, Khan FU, Ihsan AU, Zhang J (2020) Antibody–drug conjugates: a comprehensive review. Mol Cancer Res 18:3–19

    Article  CAS  PubMed  Google Scholar 

  • Kim M-J, Cho K-J, Ayala AG, Ro JY (2011) Chondrosarcoma: with updates on molecular genetics. Sarcoma 2011:405437

    PubMed  PubMed Central  Google Scholar 

  • Klein JS, Bjorkman PJ (2010) Few and far between: how HIV may be evading antibody avidity. PLoS Pathog 6:e1000908

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Koziel L, Kunath M, Kelly OG, Vortkamp A (2004) Ext1-dependent heparan sulfate regulates the range of Ihh signaling during endochondral ossification. Dev Cell 6:801–813

    Article  CAS  PubMed  Google Scholar 

  • Krol AD, Taminiau AH, Bovée JV (2008) The clinical approach towards chondrosarcoma. Oncologist 13:320–329

    Article  PubMed  Google Scholar 

  • Kronenberg HM (2003) Developmental regulation of the growth plate. Nature 423:332–336

    Article  CAS  PubMed  Google Scholar 

  • Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, Schuebbe G, Renz BW, D’Haese JG, Schloesser H, Heinemann V, Subklewe M, Boeck S, Werner J, von Bergwelt-Baildon M (2019) Advances in cancer immunotherapy 2019—latest trends. J Exp Clin Cancer Res 38:268

    Article  PubMed  PubMed Central  Google Scholar 

  • Kubo T, Sugita T, Shimose S, Matsuo T, Arihiro K, Ochi M (2008) Expression of hypoxia-inducible factor-1α and its relationship to tumour angiogenesis and cell proliferation in cartilage tumours. J Bone Jt Surg Br 90:364–370

    Article  CAS  Google Scholar 

  • Lai X, Chen S (2015) Identification of novel biomarker candidates for immunohistochemical diagnosis to distinguish low-grade chondrosarcoma from enchondroma. Proteomics 15:2358–2368

    Article  CAS  PubMed  Google Scholar 

  • Lee H-P, Lin C-Y, Shih J-S, Fong Y-C, Wang S-W, Li T-M, Tang C-H (2015) Adiponectin promotes VEGF-A-dependent angiogenesis in human chondrosarcoma through PI3K, Akt, mTOR, and HIF-α pathway. Oncotarget 6:36746–36761

    Article  PubMed  PubMed Central  Google Scholar 

  • Lee K-W, Ma L, Yan X, Liu B, Zhang X-K, Cohen P (2005) Rapid apoptosis induction by IGFBP-3 involves an insulin-like growth factor-independent nucleomitochondrial translocation of RXRα/Nur77. J Biol Chem 280:16942–16948

    Article  CAS  PubMed  Google Scholar 

  • Leerapun T, Hugate RR, Inwards CY, Scully SP, Sim FH (2007) Surgical management of conventional grade I chondrosarcoma of long bones. Clin Orthop Relat Res 463:166–172

    Article  PubMed  Google Scholar 

  • Leggon RE, Munro M, Schuerch C (2001) Thigh mass in a 52-year-old woman. Clin Orthop Relat Res 388:252–257

    Article  Google Scholar 

  • Liang X, Wang D, Wang Y, Zhou Z, Zhang J, Li J (2012) Expression of aurora kinase A and B in chondrosarcoma and its relationship with the prognosis. Diagn Pathol 7:84

    Article  PubMed  PubMed Central  Google Scholar 

  • Lichtenstein L, Bernstein D (1959) Unusual benign and malignant chondroid tumors of bone. A survey of some mesenchymal cartilage tumors and malignant chondroblastic tumors, including a few multicentric ones, as well as many atypical benign chondroblastomas and chondromyxoid fibromas. Cancer 12:1142–1157

    Article  Google Scholar 

  • Lin C-Y, Wang S-W, Chen Y-L, Chou W-Y, Lin T-Y, Chen W-C, Yang C-Y, Liu S-C, Hsieh C-C, Fong Y-C (2017) Brain-derived neurotrophic factor promotes VEGF-C-dependent lymphangiogenesis by suppressing miR-624-3p in human chondrosarcoma cells. Cell Death Dis 8:e2964–e2964

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lin C, Meitner PA, Terek RM (2002) PTEN mutation is rare in chondrosarcoma. Diagn Mol Pathol 11:22–26

    Article  PubMed  Google Scholar 

  • Lin C, McGough R, Aswad B, Block JA, Terek R (2004) Hypoxia induces HIF-1α and VEGF expression in chondrosarcoma cells and chondrocytes. J Orthop Res 22:1175–1181

    Article  CAS  PubMed  Google Scholar 

  • Liu G-T, Huang Y-L, Tzeng H-E, Tsai C-H, Wang S-W, Tang C-H (2015) CCL5 promotes vascular endothelial growth factor expression and induces angiogenesis by down-regulating miR-199a in human chondrosarcoma cells. Cancer Lett 357:476–487

    Article  CAS  PubMed  Google Scholar 

  • Liu R, Wolinsky JB, Catalano PJ, Chirieac LR, Wagner AJ, Grinstaff MW, Colson YL, Raut CP (2012) Paclitaxel-eluting polymer film reduces locoregional recurrence and improves survival in a recurrent sarcoma model: a novel investigational therapy. Ann Surg Oncol 19:199–206

    Article  PubMed  Google Scholar 

  • Lohcharoenkal W, Wang L, Chen YC, Rojanasakul Y (2014) Protein nanoparticles as drug delivery carriers for cancer therapy. BioMed Res Int 2014:180549

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Lu N, Lin T, Wang L, Qi M, Liu Z, Dong H, Zhang X, Zhai C, Wang Y, Liu L (2015) Association of SOX4 regulated by tumor suppressor miR-30a with poor prognosis in low-grade chondrosarcoma. Tumor Biol 36:3843–3852

    Article  CAS  Google Scholar 

  • Makadia HK, Siegel SJ (2011) Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymer 3:1377–1397

    Article  CAS  Google Scholar 

  • Malchenko S, Seftor EA, Nikolsky Y, Hasegawa SL, Kuo S, Stevens JW, Poyarkov S, Nikolskaya T, Kucaba T, Wang M (2012) Putative multifunctional signature of lung metastases in dedifferentiated chondrosarcoma. Sarcoma 2012:820254

    Article  PubMed  PubMed Central  Google Scholar 

  • Martinez-Sanchez A, Dudek KA, Murphy CL (2012) Regulation of human chondrocyte function through direct inhibition of cartilage master regulator SOX9 by microRNA-145 (miRNA-145). J Biol Chem 287:916–924

    Article  CAS  PubMed  Google Scholar 

  • Masui F, Ushigome S, Fujii K (1999) Clear cell chondrosarcoma: a pathological and immunohistochemical study. Histopathology 34:447–452

    Article  CAS  PubMed  Google Scholar 

  • Mcconnell BB, Gregory FJ, Stott FJ, Hara E, Peters G (1999) Induced expression of p16 INK4a inhibits both CDK4- and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes. Mol Cell Biol 19:1981–1989

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mccormick C, Leduc Y, Martindale D, Mattison K, Esford L, Dyer A, Tufaro F (1998) The putative tumour suppressor EXT1 alters the expression of cell-surface heparan sulfate. Nat Genet 19:158–161

    Article  CAS  PubMed  Google Scholar 

  • Mcewen E, Rosenthal R, Matus R (1987) A preliminary study on the evaluation of asparaginase. Cancer 59:2011–2020

    Article  Google Scholar 

  • Mcmahon AP, Ingham PW, Tabin CJ (2003) Developmental roles and clinical significance of Hedgehog signaling. Curr Top Dev Biol 53:1–114

    Article  CAS  PubMed  Google Scholar 

  • Mirra J (1989) Bone tumors clinical, radiological and pathological correlations. Lea and Febiger, Philadelphia

    Google Scholar 

  • Murphey MD, Flemming DJ, Boyea SR, Bojescul JA, Sweet DE, Temple HT (1998) Enchondroma versus chondrosarcoma in the appendicular skeleton: differentiating features. Radiographics 18:1213–1237

    Article  CAS  PubMed  Google Scholar 

  • Murphey MD, Walker EA, Wilson AJ, Kransdorf MJ, Temple HT, Gannon FH (2003) From the archives of the AFIP: imaging of primary chondrosarcoma: radiologic–pathologic correlation. Radiographics 23:1245–1278

    Article  PubMed  Google Scholar 

  • Nakashima Y, Unni KK, Shives TC, Swee RG, Dahlin DC (1986) Mesenchymal chondrosarcoma of bone and soft tissue. A review of 111 cases. Cancer 57:2444–2453

    Article  CAS  PubMed  Google Scholar 

  • Naumann S, Krallman PA, Unni KK, Fidler ME, Neff JR, Bridge JA (2002) Translocation der (13; 21)(q10; q10) in skeletal and extraskeletal mesenchymal chondrosarcoma. Mod Pathol 15:572–576

    Article  PubMed  Google Scholar 

  • Ng JM, Curran T (2011) The Hedgehog’s tale: developing strategies for targeting cancer. Nat Rev Cancer 11:493–501

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nishio J, Reith JD, Ogose A, Maale G, Neff JR, Bridge JA (2005) Cytogenetic findings in clear cell chondrosarcoma. Cancer Genet Cytogenet 162:74–77

    Article  CAS  PubMed  Google Scholar 

  • Norman A, Sissons H (1984) Radiographic hallmarks of peripheral chondrosarcoma. Radiology 151:589–596

    Article  CAS  PubMed  Google Scholar 

  • Overstreet D, von Recum H, Vernon B (2011) 5—Drug delivery applications of injectable biomaterials. Woodhead Publishing, Sawston

    Book  Google Scholar 

  • Ozaki T, Hillmann A, Lindner N, Blasius S, Winkelmann W (1996) Metastasis of chondrosarcoma. J Cancer Res Clin Oncol 122:625–628

    Article  CAS  PubMed  Google Scholar 

  • Padma VV (2015) An overview of targeted cancer therapy. Biomedicine (Taipei) 5:1–6

    Article  Google Scholar 

  • Park H-R, Park Y-K (2007) Differential expression of runx2 and Indian hedgehog in cartilaginous tumors. Pathol Oncol Res 13:32–37

    Article  CAS  PubMed  Google Scholar 

  • Perez J, Decouvelaere AV, Pointecouteau T, Pissaloux D, Michot JP, Besse A, Blay JY, Dutour A (2012) Inhibition of chondrosarcoma growth by mTOR inhibitor in an in vivo syngeneic rat model. PLoS ONE 7:e32458

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pieretti JC, Rolim WR, Ferreira FF, Lombello CB, Nascimento MH, Seabra AB (2019) Synthesis, characterization, and cytotoxicity of Fe3O4@Ag hybrid nanoparticles: promising applications in cancer treatment. J Clust Sci 31(2):1–13

    Google Scholar 

  • Pyne NJ, Mcnaughton M, Boomkamp S, Macritchie N, Evangelisti C, Martelli AM, Jiang H-R, Ubhi S, Pyne S (2016) Role of sphingosine 1-phosphate receptors, sphingosine kinases and sphingosine in cancer and inflammation. Adv Biol Regul 60:151–159

    Article  CAS  PubMed  Google Scholar 

  • Resnick D (1988) Tumors and tumor-like lesions of bone. Springer, Berlin

    Google Scholar 

  • Şahin Ş, Bilgiç E, Salimi K, Tuncel A, Karaosmanoğlu B, Taşkıran EZ, Korkusuz P, Korkusuz F (2019) Development, characterization and research of efficacy on in vitro cell culture of glucosamine carrying hyaluronic acid nanoparticles. J Drug Deliv Sci Technol 52:393–402

    Article  CAS  Google Scholar 

  • Sandberg AA, Bridge JA (2003) Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: chondrosarcoma and other cartilaginous neoplasms. Cancer Genet Cytogenet 143:1–31

    Article  CAS  PubMed  Google Scholar 

  • Sandberg AA (2004) Genetics of chondrosarcoma and related tumors. Curr Opin Oncol 16:342–354

    Article  PubMed  Google Scholar 

  • Schrage YM, Briaire-De Bruijn IH, De Miranda NF, Van Oosterwijk J, Taminiau AH, Van Wezel T, Hogendoorn PC, Bovée JV (2009a) Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. Cancer Res 69:6216–6222

    Article  CAS  PubMed  Google Scholar 

  • Schrage YM, Lam S, Jochemsen AG, Cleton-Jansen AM, Taminiau AH, Hogendoorn PC, Bovée JV (2009b) Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro. J Cell Mol Med 13:2843–2852

    Article  CAS  PubMed  Google Scholar 

  • Schrage YM, Machado I, Meijer D, Briaire-De Bruijn I, Van Den Akker BE, Taminiau AH, Kalinski T, Llombart-Bosch A, Bovée JV (2010) COX-2 expression in chondrosarcoma: a role for celecoxib treatment? Eur J Cancer 46:616–624

    Article  CAS  PubMed  Google Scholar 

  • Schuetze SM, Bolejack V, Choy E, Ganjoo KN, Staddon AP, Chow WA, Tawbi HA, Samuels BL, Patel SR, von Mehren M (2017) Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor. Cancer 123:90–97

    Article  CAS  PubMed  Google Scholar 

  • Schwartz HS, Zimmerman NB, Simon M, Wroble R, Millar E, Bonfiglio M (1987) The malignant potential of enchondromatosis. J Bone Jt Surg Am 69:269–274

    Article  CAS  Google Scholar 

  • Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S (2015) Advances and challenges of liposome assisted drug delivery. Front Pharmacol 6:286

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Sha B, Gao W, Han Y, Wang S, Wu J, Xu F, Lu T (2013) Potential application of titanium dioxide nanoparticles in the prevention of osteosarcoma and chondrosarcoma recurrence. J Nanosci Nanotechnol 13:1208–1211

    Article  CAS  PubMed  Google Scholar 

  • Shapira A, Livney YD, Broxterman HJ, Assaraf YG (2011) Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Update 14:150–163

    Article  CAS  Google Scholar 

  • Shapiro CL (2018) Cancer survivorship. N Engl J Med 379:2438–2450

    Article  PubMed  Google Scholar 

  • Sharma A, Goyal AK, Rath G (2018) Recent advances in metal nanoparticles in cancer therapy. J Drug Target 26:617–632

    Article  CAS  PubMed  Google Scholar 

  • Shield WP III, Cellini A, Tian H, Wilson K, Dan Y, Abzug JM, Garcia S, Moritani N, Alferiev I, Chorny M, Takigawa M, Ng VY, Iwamoto M, Enomoto-Iwamoto M (2019) Selective agonists of nuclear retinoic acid receptor gamma inhibit growth of HCS-2/8 chondrosarcoma Cells. J Orthop Res 38(5):1045–1051

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Shinaver C, Mafee M, Choi K (1997) MRI of mesenchymal chondrosarcoma of the orbit: case report and review of the literature. Neuroradiology 39:296–301

    Article  CAS  PubMed  Google Scholar 

  • Shinohara N, Maeda S, Yahiro Y, Sakuma D, Matsuyama K, Imamura K, Kawamura I, Setoguchi T, Ishidou Y, Nagano S (2017) TGF-β signalling and PEG10 are mutually exclusive and inhibitory in chondrosarcoma cells. Sci Rep 7:1–12

    Article  CAS  Google Scholar 

  • Shor AC, Keschman EA, Lee FY, Muro-Cacho C, Letson GD, Trent JC, Pledger WJ, Jove R (2007) Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res 67:2800–2808

    Article  CAS  PubMed  Google Scholar 

  • Simamora P, Alvarez JM, Yalkowsky SH (2001) Solubilization of rapamycin. Int J Pharm 213:25–29

    Article  CAS  PubMed  Google Scholar 

  • Skubitz KM (2003) Phase II trial of PEGylated-liposomal doxorubicin (Doxil™) In sarcoma. Cancer Investig 21:167–176

    Article  CAS  Google Scholar 

  • Subhawong TK, Fishman EK, Swart JE, Carrino JA, Attar S, Fayad LM (2010) Soft-tissue masses and mass like conditions: what does CT add to diagnosis and management? Am J Roentgenol 194:1559–1567

    Article  Google Scholar 

  • Swierczewska M, Han H, Kim K, Park J, Lee S (2016) Polysaccharide-based nanoparticles for theranostic nanomedicine. Adv Drug Deliv Rev 99:70–84

    Article  CAS  PubMed  Google Scholar 

  • Tang C-H, Yamamoto A, Lin Y-T, Fong Y-C, Tan T-W (2010) Involvement of matrix metalloproteinase-3 in CCL5/CCR5 pathway of chondrosarcomas metastasis. Biochem Pharmacol 79:209–217

    Article  CAS  PubMed  Google Scholar 

  • Terek RM, Healey JH, Garin-Chesa P, Mak S, Huvos A, Albino AP (1998) p53 mutations in chondrosarcoma. Am J Surg Pathol 7:51–56

    CAS  Google Scholar 

  • Thornton K, Chen AR, Trucco M, Shah P, Wilky BA, Gul N, Carrera-Haro M, Ferreira MF, Shafique U, Powell J (2013) A dose-finding study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcoma. Int J Cancer 133:997–1005

    Article  CAS  PubMed  Google Scholar 

  • Tiet TD, Hopyan S, Nadesan P, Gokgoz N, Poon R, Lin AC, Yan T, Andrulis IL, Alman BA, Wunder JS (2006) Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation. Am J Pathol 168:321–330

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tran S, Degiovanni P-J, Piel B, Rai P (2017) Cancer nanomedicine: a review of recent success in drug delivery. Clin Transl Med 6:44

    Article  PubMed  PubMed Central  Google Scholar 

  • Trucco MM, Meyer CF, Thornton KA, Shah P, Chen AR, Wilky BA, Carrera-Haro MA, Boyer LC, Ferreira MF, Shafique U (2018) A phase II study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcomas. Clin Sarcoma Res 8:21

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tsai CH, Yang DY, Lin CY, Chen TM, Tang CH, Huang YL (2017) Sphingosine-1-phosphate suppresses chondrosarcoma metastasis by upregulation of tissue inhibitor of metalloproteinase 3 through suppressing miR-101 expression. Mol Oncol 11:1380–1398

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tsavaris O, Economopoulou P, Kotsantis I, Reppas L, Avgerinou C, Spathas N, Prevezanou M, Psyrri A (2018) Clinical benefit of pazopanib in a patient with metastatic chondrosarcoma: a case report and review of the literature. Front Oncol 8:45

    Article  PubMed  PubMed Central  Google Scholar 

  • Unni K, Dahlin D, Beabout J, Sim F (1976) Chondrosarcoma: clear-cell variant. A report of sixteen cases. J Bone Jt Surg Am 58:676–683

    Article  CAS  Google Scholar 

  • Van Beerendonk HM, Rozeman LB, Taminiau AH, Sciot R, Bovée JV, Cleton-Jansen AM, Hogendoorn PC (2004) Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression. J Pathol 202:359–366

    Article  PubMed  CAS  Google Scholar 

  • Van Maldegem AM, Gelderblom H, Palmerini E, Dijkstra SD, Gambarotti M, Ruggieri P, Nout RA, Van De Sande MA, Ferrari C, Ferrari S (2014) Outcome of advanced, unresectable conventional central chondrosarcoma. Cancer 120:3159–3164

    Article  PubMed  CAS  Google Scholar 

  • Vares G, Jallet V, Matsumoto Y, Rentier C, Takayama K, Sasaki T, Hayashi Y, Kumada H, Sugawara H (2018) Functionalized mesoporous silica nanoparticles for innovative boron-neutron capture therapy of resistant cancers. bioRxiv:471128

  • Veth R, Schreuder B, van Beem H, Pruszczynski M, de Rooy J (2005) Cryosurgery in aggressive, benign, and low-grade malignant bone tumours. Lancet Oncol 6:25–34

    Article  PubMed  Google Scholar 

  • Wadayama B, Toguchida J, Yamaguchi T, Sasaki M, Yamamuro T (1993) p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas. Br J Cancer 68:1134–1139

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wagner MJ, Ricciotti RW, Mantilla J, Loggers ET, Pollack SM, Cranmer LD (2018) Response to PD1 inhibition in conventional chondrosarcoma. J Immunother Cancer 6:1–4

    Article  Google Scholar 

  • Wang C-Q, Huang Y-W, Wang S-W, Huang Y-L, Tsai C-H, Zhao Y-M, Huang B-F, Xu G-H, Fong Y-C, Tang C-H (2017) Amphiregulin enhances VEGF-A production in human chondrosarcoma cells and promotes angiogenesis by inhibiting miR-206 via FAK/c-Src/PKCδ pathway. Cancer Lett 385:261–270

    Article  CAS  PubMed  Google Scholar 

  • Wehrli BM, Huang W, De Crombrugghe B, Ayala AG, Czerniak B (2003) Sox9, a master regulator of chondrogenesis, distinguishes mesenchymal chondrosarcoma from other small blue round cell tumors. Hum Pathol 34:263–269

    Article  CAS  PubMed  Google Scholar 

  • Weinberg RA (1995) The retinoblastoma protein and cell cycle control. Cell 81:323–330

    Article  CAS  PubMed  Google Scholar 

  • Weiner S (2004) Enchondroma and chondrosarcoma of bone: clinical, radiologic, and histologic differentiation. Instr Course Lect 53:645–649

    PubMed  Google Scholar 

  • Wu F, Zhang Y, Sun B, Mcmahon AP, Wang Y (2017) Hedgehog signaling: from basic biology to cancer therapy. Cell Chem Biol 24:252–280

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wyman JJ, Hornstein AM, Meitner PA, Mak S, Verdier P, Block JA, Pan J, Terek RM (1999) Multidrug resistance-1 and p-glycoprotein in human chondrosarcoma cell lines: expression correlates with decreased intracellular doxorubicin and in vitro chemoresistance. J Orthop Res 17:935–940

    Article  CAS  PubMed  Google Scholar 

  • Yamaguchi T, Toguchida J, Wadayama B, Kanoe H, Nakayama T, Ishizaki K, Ikenaga M, Kotoura Y, Sasaki MS (1996) Loss of heterozygosity and tumor suppressor gene mutations in chondrosarcomas. Anticancer Res 16:2009–2015

    CAS  PubMed  Google Scholar 

  • Yang J, Li S, Wang B, Wu Y, Chen Z, Lv M, Lin Y, Yang J (2016a) Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer. Tumor Biol 37:11645–11655

    Article  CAS  Google Scholar 

  • Yang K, Tang X-D, Guo W, Xu X-L, Ren T-T, Ren C-M, Wang S-D, Bao X, Zhang F, Sun K-K (2016b) BMPR2-pSMAD1/5 signaling pathway regulates RUNX2 expression and impacts the progression of dedifferentiated chondrosarcoma. Am J Cancer Res 6:1302

    CAS  PubMed  PubMed Central  Google Scholar 

  • Yang W-H, Chen J-C, Hsu K-H, Lin C-Y, Wang S-W, Wang S-J, Chang Y-S, Tang C-H (2014) Leptin increases VEGF expression and enhances angiogenesis in human chondrosarcoma cells. Biochim Biophys Acta 1840:3483–3493

    Article  CAS  PubMed  Google Scholar 

  • Yang W-H, Chang A-C, Wang S-W, Wang S-J, Chang Y-S, Chang T-M, Hsu S-K, Fong Y-C, Tang C-H (2016c) Leptin promotes VEGF-C production and induces lymphangiogenesis by suppressing miR-27b in human chondrosarcoma cells. Sci Rep 6:28647

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhang Y-X, Van Oosterwijk JG, Sicinska E, Moss S, Remillard SP, Van Wezel T, Bühnemann C, Hassan AB, Demetri GD, Bovée JV (2013) Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy. Clin Cancer Res 19:3796–3807

    Article  CAS  PubMed  Google Scholar 

  • Zugazagoitia J, Guedes C, Ponce S, Ferrer I, Molina-Pinelo S, Paz-Ares L (2016) Current challenges in cancer treatment. Clin Ther 38:1551–1566

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the Research Fund of Chungnam National University.

Author information

Author notes

  1. Dong Hyun Kim and Han Sol Lee contributed equally to this work.

Authors and Affiliations

  1. College of Pharmacy, Chungnam National University, Daejeon, 34134, Republic of Korea

    Dong Hyun Kim, Han Sol Lee, Yong-Hyeon Mun, SeokJin Koh, Joon-Sun Park, Sang Min Lee, Cheong-Weon Cho & Jae-Young Lee

  2. College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, 08826, Republic of Korea

    Nae-Won Kang, Mee Yeon Lee & Dae-Duk Kim

  3. Department of Pharmacy, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, 07061, Republic of Korea

    Mee Yeon Lee

Authors
  1. Dong Hyun Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Han Sol Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yong-Hyeon Mun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. SeokJin Koh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Joon-Sun Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sang Min Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nae-Won Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mee Yeon Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Cheong-Weon Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Dae-Duk Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jae-Young Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jae-Young Lee.

Ethics declarations

Conflicts of interest

The authors declare that they have no conflict of interest.

Statement of human and animal rights

This article does not contain any studies with human and animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, D.H., Lee, H.S., Mun, YH. et al. An overview of chondrosarcoma with a focus on nanoscale therapeutics. J. Pharm. Investig. 50, 537–552 (2020). https://doi.org/10.1007/s40005-020-00492-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40005-020-00492-x

Keywords

Search

Navigation